AnaptysBio, Inc. NASDAQ:ANAB

AnaptysBio stock price today

$19.79
+6.75
+51.76%
Financial Health
0
1
2
3
4
5
6
7
8
9

AnaptysBio stock price monthly change

-56.68%
month

AnaptysBio stock price quarterly change

-56.68%
quarter

AnaptysBio stock price yearly change

-40.35%
year

AnaptysBio key metrics

Market Cap
434.52M
Enterprise value
551.76M
P/E
-4.79
EV/Sales
53.63
EV/EBITDA
-5.24
Price/Sales
58.67
Price/Book
2.30
PEG ratio
0.04
EPS
-6.14
Revenue
22.96M
EBITDA
-145.43M
Income
-163.3M
Revenue Q/Q
422.48%
Revenue Y/Y
114.77%
Profit margin
-1251.33%
Oper. margin
-1119.41%
Gross margin
0%
EBIT margin
-1119.41%
EBITDA margin
-633.37%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

AnaptysBio stock price history

AnaptysBio stock forecast

AnaptysBio financial statements

Average Price Target
Last Year

$55.33

Potential upside: 179.60%

Based on estimate of 6 analysts
  • Analysts Price target

  • Financials & Ratios estimates

AnaptysBio, Inc. (NASDAQ:ANAB): Profit margin
Jun 2023 3.46M -39.84M -1151.59%
Sep 2023 3.31M -37.30M -1124.41%
Dec 2023 9.00M -42.21M -468.75%
Mar 2024 7.17M -43.93M -612.01%
AnaptysBio, Inc. (NASDAQ:ANAB): Earnings per share (EPS)
2024-03-11 -1.74 -1.59
AnaptysBio, Inc. (NASDAQ:ANAB): Debt to assets
Jun 2023 517100000 368.65M 71.29%
Sep 2023 487326000 366.94M 75.3%
Dec 2023 452389000 364.28M 80.52%
Mar 2024 405835000 358.05M 88.23%
AnaptysBio, Inc. (NASDAQ:ANAB): Cash Flow
Jun 2023 -25.40M -20.45M -13.49M
Sep 2023 -36.47M 30.63M -3.07M
Dec 2023 -34.34M 49.17M -5.15M
Mar 2024 -44.19M 68.61M -6.69M

AnaptysBio alternative data

AnaptysBio, Inc. (NASDAQ:ANAB): Employee count
Aug 2023 96
Sep 2023 96
Oct 2023 96
Nov 2023 96
Dec 2023 96
Jan 2024 96
Feb 2024 96
Mar 2024 117
Apr 2024 117
May 2024 117
Jun 2024 117
Jul 2024 117

AnaptysBio other data

100.00% 0.00%
of ANAB is owned by hedge funds
29.73M +1.97M
shares is hold by hedge funds

AnaptysBio, Inc. (NASDAQ:ANAB): Insider trades (number of shares)
Period Buy Sel
Jan 2024 0 16970
Feb 2024 0 5000
Mar 2024 0 148940
May 2024 0 1500
Jun 2024 0 3900
Jul 2024 0 11500
Aug 2024 273972 2000
Sep 2024 0 28440
Nov 2024 0 10000
Transaction Date Insider Security Shares Price per share Total value Source
Option
RENTON HOLLINGS director
Common Stock 10,000 $6.93 $69,300
Option
RENTON HOLLINGS director
Common Stock 10,000 $6.93 $69,300
Sale
RENTON HOLLINGS director
Common Stock 10,000 $25 $250,000
Option
LIZZUL PAUL F. officer: Chief Me.. Common 1,500 $18.5 $27,750
Option
LIZZUL PAUL F. officer: Chief Me.. Common Stock 1,500 $18.5 $27,750
Sale
LIZZUL PAUL F. officer: Chief Me.. Common Stock 1,500 $38.67 $58,005
Sale
LOUMEAU ERIC J officer: CHIEF LEGAL OFFICER
Common Stock 3,780 $38.41 $145,190
Option
LOUMEAU ERIC J officer: CHIEF LEGAL OFFICER
Employee Stock Option (right to buy) 5,000 $14.02 $70,100
Option
LOUMEAU ERIC J officer: CHIEF LEGAL OFFICER
Common Stock 5,000 $14.02 $70,100
Sale
LOUMEAU ERIC J officer: CHIEF LEGAL OFFICER
Common Stock 2,220 $38.93 $86,425
Patent
Application
Filling date: 4 Jun 2020 Issue date: 28 Jul 2022
Application
Filling date: 27 Oct 2021 Issue date: 2 Jun 2022
Application
Filling date: 27 Apr 2018 Issue date: 5 May 2022
Application
Filling date: 27 Sep 2021 Issue date: 24 Mar 2022
Application
Filling date: 26 Aug 2021 Issue date: 16 Dec 2021
Grant
Filling date: 1 Nov 2017 Issue date: 26 Oct 2021
Grant
Filling date: 18 Nov 2019 Issue date: 28 Sep 2021
Application
Filling date: 13 Jul 2020 Issue date: 3 Jun 2021
Application
Filling date: 19 Oct 2020 Issue date: 1 Apr 2021
Application
Filling date: 15 Oct 2020 Issue date: 11 Feb 2021
Thursday, 12 December 2024
zacks.com
Wednesday, 11 December 2024
benzinga.com
reuters.com
reuters.com
globenewswire.com
Monday, 25 November 2024
zacks.com
Friday, 8 November 2024
zacks.com
zacks.com
Tuesday, 5 November 2024
zacks.com
globenewswire.com
globenewswire.com
Thursday, 29 August 2024
globenewswire.com
Friday, 23 August 2024
fool.com
Thursday, 15 August 2024
seekingalpha.com
Wednesday, 14 August 2024
globenewswire.com
Monday, 5 August 2024
zacks.com
globenewswire.com
Monday, 29 July 2024
zacks.com
Monday, 22 July 2024
benzinga.com
Thursday, 9 May 2024
Zacks Investment Research
Wednesday, 1 May 2024
Zacks Investment Research
Monday, 15 April 2024
InvestorPlace
Friday, 12 April 2024
The Motley Fool
Tuesday, 9 April 2024
Zacks Investment Research
Thursday, 14 March 2024
Zacks Investment Research
Zacks Investment Research
Monday, 11 March 2024
Zacks Investment Research
Thursday, 29 February 2024
GlobeNewsWire
Wednesday, 28 February 2024
Zacks Investment Research
Monday, 19 February 2024
Zacks Investment Research
  • What's the price of AnaptysBio stock today?

    One share of AnaptysBio stock can currently be purchased for approximately $19.79.

  • When is AnaptysBio's next earnings date?

    Unfortunately, AnaptysBio's (ANAB) next earnings date is currently unknown.

  • Does AnaptysBio pay dividends?

    No, AnaptysBio does not pay dividends.

  • How much money does AnaptysBio make?

    AnaptysBio has a market capitalization of 434.52M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 66.78% to 17.16M US dollars. AnaptysBio made a loss 163.62M US dollars in net income (profit) last year or -$1.59 on an earnings per share basis.

  • What is AnaptysBio's stock symbol?

    AnaptysBio, Inc. is traded on the NASDAQ under the ticker symbol "ANAB".

  • What is AnaptysBio's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of AnaptysBio?

    Shares of AnaptysBio can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are AnaptysBio's key executives?

    AnaptysBio's management team includes the following people:

    • Mr. Hamza Suria Pres, Chief Executive Officer & Director(age: 49, pay: $885,390)
    • Mr. Dennis M. Mulroy Chief Financial Officer(age: 70, pay: $448,810)
    • Dr. Paul F. Lizzul Chief Medical Officer(age: 50, pay: $339,760)
  • How many employees does AnaptysBio have?

    As Jul 2024, AnaptysBio employs 117 workers.

  • When AnaptysBio went public?

    AnaptysBio, Inc. is publicly traded company for more then 8 years since IPO on 26 Jan 2017.

  • What is AnaptysBio's official website?

    The official website for AnaptysBio is anaptysbio.com.

  • Where are AnaptysBio's headquarters?

    AnaptysBio is headquartered at 10770 Wateridge Circle, San Diego, CA.

  • How can i contact AnaptysBio?

    AnaptysBio's mailing address is 10770 Wateridge Circle, San Diego, CA and company can be reached via phone at 858 362 6295.

  • What is AnaptysBio stock forecast & price target?

    Based on 6 Wall Street analysts` predicted price targets for AnaptysBio in the last 12 months, the avarage price target is $55.33. The average price target represents a 179.60% change from the last price of $19.79.

AnaptysBio company profile:

AnaptysBio, Inc.

anaptysbio.com
Exchange:

NASDAQ

Full time employees:

117

Industry:

Biotechnology

Sector:

Healthcare

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

10770 Wateridge Circle
San Diego, CA 92121-5801

CIK: 0001370053
ISIN: US0327241065
CUSIP: 032724106